Do you want to read an article? Please log in or register.
Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis
Gallbladder and Biliary Diseases
Indications
Related content
Gallbladder and Biliary DiseasesHepatology
Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome
Am J Gastroenterol.
Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC1, Hirschfield GM, Hansen BE, van Buuren HR
doi: 10.1038/ajg.2017.440.
Gallbladder and Biliary Diseases
Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis
BMC Gastroenterol.
Fujino H, Tanaka M, Imamura M, Morio K, Ono A, Nakahara T, Murakami E, Kawaoka T, Takahashi S, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K
doi: 10.1186/s12876-019-1092-z.
RECOMMENDED
Gallbladder and Biliary Diseases
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
Lancet Gastroenterol Hepatol.
Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D
doi: 10.1016/S2468-1253(19)30094-9.
Gallbladder and Biliary DiseasesHepatology
Factors Associated With Progression and Outcomes of Early-stage Primary Biliary Cholangitis
Clin Gastroenterol Hepatol.
Gatselis NK, Goet JC, Zachou K, Lammers WJ, Janssen HLA, Hirschfield G, Corpechot C, Lindor KD, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Lygoura V, Nevens F, Mason AL, Kowdley KV, Ponsioen CY, Bruns T, Thorburn D, Verhelst X, Harms MH, van Buuren HR, Hansen BE, Dalekos GN, Global PBC Study Group.
doi: 10.1016/j.cgh.2019.08.013.
Gallbladder and Biliary Diseases
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Lancet Gastroenterol Hepatol.
Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F, Cardinale V, Ainsworth HF, Heneghan MA, Thorburn D, Bathgate A, Jones R, Neuberger JM, Battezzati PM, Zuin M, Taylor-Robinson S, Donato MF, Kirby J, Mitchell-Thain R, Floreani A, Sampaziotis F, Muratori L, Alvaro D, Marzioni M, Miele L, Marra F, Giannini E, Gaudio E, Ronca V, Bonato G, Cristoferi L, Malinverno F, Gerussi A, Stocken DD, Cordell HJ, Hirschfield GM, Alexander GJ, Sandford RN, Jones DE, Invernizzi P, Mells GF; Italian PBC Study Group and the UK–PBC Consortium.
doi: 10.1016/S2468-1253
Gallbladder and Biliary Diseases
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Hepatology.
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M
doi: 10.1002/hep.30145.
Inflammatory Bowel Disease
Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study
J Crohns Colitis.
Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, Gutiérrez A, Gordillo Ábalos J, de Castro L, Iborra M, Carbajo AY, Taxonera C, Rodríguez-Lago I, Mesonero F, de Francisco R, Gómez-Gómez GJ, Chaparro M, Tardillo CA, Rivero M, Algaba A, Martín Arranz E, Cañete F, Vicente R, Sicilia B, Antolín B, Prieto V, Márquez L, Benítez JM, Camo P, Piqueras M, Gargallo CJ, Hinojosa E, Huguet JM, Pérez Calle JL, Van Domselaar M, Rodriguez C, Calvet X, Muñoz-Villafranca C, García-Sepulcre MF, Munoz-Garrido P, Fernández-Clotet A, Gómez Irwin L, Hernández S, Guardiola J, Sempere L, González Muñoza C, Hernández V, Beltrán B, Barrio J, Alba C, Moraleja I, López-Sanromán A, Riestra S, Martínez Montiel P, Garre A, Arranz L, García MJ, Martín Arranz MD, Corsino P, Arias L, Fernández-Salazar L, Fernández-Pordomingo A, Andreu M, Iglesias E, Ber Y, Mena R, Arroyo Villarino MT, Mora M, Ruiz L, López-Serrano P, Blazquez I, Villoria A, Fernández M, Bermejo F, Banales JM, Domènech E, Gisbert JP, Spanish GETECCU group (ENEIDA Project).
doi: 10.1093/ecco-jcc/jjz094.
Gallbladder and Biliary Diseases
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase
Am J Gastroenterol.
Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE, GLOBAL PBC Study Group.
doi: 10.14309/ajg.
HepatologyInflammatory Bowel Disease
Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
Clin Gastroenterol Hepatol.
Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, International Primary Sclerosing Cholangitis Study Group (IPSCSG)., Levy C
doi: 10.1016/j.cgh.2019.05.013.